Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial

• Published in: Blood 2016-08, Vol.128 (8), p.1050-1058
• Main Authors: Alvarnas, Joseph C., Le Rademacher, Jennifer, Wang, Yanli, Little, Richard F., Akpek, Gorgun, Ayala, Ernesto, Devine, Steven, Baiocchi, Robert, Lozanski, Gerard, Kaplan, Lawrence, Noy, Ariela, Popat, Uday, Hsu, Jack, Morris, Lawrence E., Thompson, Jason, Horowitz, Mary M., Mendizabal, Adam, Levine, Alexandra, Krishnan, Amrita, Forman, Stephen J., Navarro, Willis H., Ambinder, Richard
• Format: Article
• Language: English
• Subjects: Adult; Bone Marrow Transplantation - adverse effects; Bone Marrow Transplantation - mortality; CD4 Lymphocyte Count; Clinical Trials and Observations; Databases as Topic; Demography; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation - adverse effects; Hematopoietic Stem Cell Transplantation - mortality; Humans; Lymphoma, AIDS-Related - immunology; Lymphoma, AIDS-Related - mortality; Lymphoma, AIDS-Related - therapy; Male; Middle Aged; Transplantation, Autologous - adverse effects; Treatment Outcome; Viral Load - immunology; Young Adult
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2015-08-664706

Autologous hematopoietic cell transplant (AHCT) for HIV-infected patients is largely limited to centers with HIV-specific expertise. The Blood and Marrow Transplant Clinical Trials Network 0803/AIDS Malignancy Consortium 071 trial is a multicenter phase 2 study of AHCT for patients with HIV-related lymphoma (HRL). Eligible patients had chemotherapy-sensitive relapsed/persistent HRL, were >15 years of age, and had treatable HIV infection. Patients were prepared using carmustine, etoposide, cytarabine, and melphalan and received consistent management of peritransplant antiretroviral treatment. The primary endpoint was 1-year overall survival. Forty-three patients were enrolled; 40 underwent AHCT. Pretransplant HIV viral load was undetectable (